ERBB2 and breast carcinoma: Compared with the other subtypes, HER2+ breast cancers achieve higher rates of pCR [5], with the rates that vary between clinical trials being estimated to reach 50% with taxanes-anthracyclines-based regimens in association with trastuzumab [8,9,10].